CMIC
Providing end-to-end healthcare solutions to accelerate drug development and patient access.
| JPY | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | 13 % | 26 % | (3 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | 10 % | 12 % | 17 % | 14 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | 2 % | 2 % | 8 % | 7 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
CMIC Group, established in 1992 as Japan’s first Contract Research Organization (CRO), has since evolved into a comprehensive healthcare solutions provider supporting every stage of the pharmaceutical value chain. With a mission to bring innovative therapies to patients faster, CMIC offers a wide range of services including drug discovery support, clinical trial management, site management (SMO), contract development and manufacturing (CDMO), regulatory consulting, and commercialization solutions. Operating not only in Japan but across Asia, the U.S., and other global markets, CMIC partners with pharmaceutical, biotech, and medical device companies to streamline development processes, reduce costs, and ensure quality and compliance. Their unique "Pharmaceutical Value Creator (PVC)" model integrates scientific expertise, operational excellence, and strategic insight to accelerate product development and improve healthcare outcomes. With decades of industry experience, CMIC remains committed to driving innovation and value throughout the life sciences industry.
Keywords: CMIC Group, CRO, CDMO, SMO, pharmaceutical services, drug development, clinical trials, healthcare solutions, regulatory consulting, biotech support.
